NorthlineHealth
Join
← FormularyTracking · Category 2

Anxiolytic Peptide · Tuftsin Analogue

Selank

Anxiolytic, cognitive

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

Selank is a synthetic heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg) developed alongside Semax. It stabilizes enkephalins (endogenous opioids), upregulates IL-6 and BDNF, and modulates GABA-A receptor activity — producing anxiolytic effects without the sedation or dependence risk of benzodiazepines in animal models.

Indications

→Anxiety and stress reduction
→Cognitive function under stress
→Immune modulation via tuftsin activity
→Depression and mood support (research)

Regulatory status

Selank is approved in Russia as a nasal anxiolytic. No FDA approval exists in the US. It is on the 503A Category 2 list and cannot be compounded for clinical use. Northline tracks reclassification.

References

01Semenova TP, et al. Selank regulates BDNF/trkB expression in rats subjected to chronic unpredictable stress. Bull Exp Biol Med. 2009.
02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.